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undifferentiated thyroid carcinoma
Jesús Espinal-Enríquez1,2, Said Muñoz-Montero1, Ivan Imaz-Rosshandler1, Aldo Huerta-Verde1,
Carmen Mejía3† and Enrique Hernández-Lemus1,2*†
Abstract
Background: Thyroid cancer (TC) is the most common malignant cancer of the Endocrine System. Histologically,
there are three main subtypes of TC: follicular, papillary and anaplastic. Diagnosing a thyroid tumor subtype with a
high level of accuracy and confidence is still a difficult task because genetic, molecular and cellular mechanisms
underlying the transition from differentiated to undifferentiated thyroid tumors are not well understood.
A genome-wide analysis of these three subtypes of thyroid carcinoma was carried out in order to identify significant
differences in expression levels as well as enriched pathways for non-shared molecular and cellular features between
subtypes.
Results: Inhibition of matrix metalloproteinases pathway is a major event involved in thyroid cancer progression and
its dysregulation may result crucial for invasiveness, migration and metastasis. This pathway is drastically altered in
ATC while in FTC and PTC, the most important pathways are related to DNA-repair activation or cell to cell
signaling events.
Conclusion: A progression from FTC to PTC and then to ATC was detected and validated on two independent
datasets. Moreover, PTX3, COLEC12 and PDGFRA genes were found as possible candidates for biomarkers of ATC
while GPR110 could be tested to distinguish PTC over other tumor subtypes. The genome-wide analysis emphasizes
the preponderance of pathway-dysregulation mechanisms over simple gene-malfunction as the main mechanism
involved in the development of a cancer phenotype.
Keywords: Anaplastic thyroid cancer, Inhibition of matrix metalloproteinases, Pathway analysis, Thyroid carcinoma
progression, Genome-wide analysis
Background
Thyroid cancer (TC) is the most common malignant
tumor of the endocrine system. TC is currently presenting
an unexplained incidence. Although it can occur at any
age, onset is more common after 30 y.o.; its aggressiveness
significantly increasing in elderly patients. TC does not
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always cause symptoms being its first sign a thyroid
nodule.
Thyroid neoplasms are histologically classified into fol-
licular adenoma (FA), follicular thyroid cancer (FTC),
papillary thyroid cancer (PTC) and anaplastic thyroid can-
cer (ATC). FTC and PTC are differentiated tumors with
low risk of recurrence and good prognosis. On the other
hand, ATC is an undifferentiated thyroid cancer, usually
diagnosed at an advanced stage and thus not responding
to chemotherapy; therefore frequently leading to a fatal
prognosis [1]. Prognosis is related to stage at diagnosis and
5-year survival is 99% for patients with localized disease
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versus 58% for patients with distant metastases. Almost
all differentiated thyroid carcinomas can be suppressed
either by surgery, replacement therapy through thyroid
stimulating hormone (TSH) or iodine-131 treatment. To
date, physicians continue to face two major problems
when trying to determine the best management strategy
for patients with thyroid nodules. The first one is to deter-
mine the type of ailment. In fact, 15-30 % of thyroid nod-
ules evaluated by fine-needle aspiration cytology are not
clearly benign or malignant [2]. A second dilemma is the
identification of the most aggressive cases, mainly papil-
lary and anaplastic thyroid tumors. These could be treated
undergoing relentless therapy and follow-up instead of
invasive and costly procedures [3].
Thyroid tumors result from the accumulation of a vari-
ety of genetic and epigenetic alterations that lead to
gain-of-function in oncogenes and loss-of-function in
tumor suppressor genes. An understanding of the dif-
ferent events involved in gene pathways would advance
knowledge of thyroid cancer and therefore, improve the
strategic course of treatment since to this date a reli-
able molecular test to depict differences in adenomatoid
nodule, adenoma, and carcinoma has not been developed
[4,5].
Follicular Carcinoma. It accounts for 5-15% of thyroid
carcinomas overall. Mutations of the RAS proto-oncogene
have been linked to follicular thyroid carcinoma in up
to 80% follicular tumors [3]. The presence of the RAS
mutation does not differentiate follicular carcinoma from
follicular adenoma but is thought to play an important
role in the transformation of follicular cells into carci-
noma [6]. Moreover, PAX8 is a transcription factor that
is essential for normal thyroid gland development when
fusion protein with PPAR-γ has shown to be oncogenic
[7]. PTEN gene activation of the PI3K/AKT signaling
pathway is thought to promote the development of follic-
ular and anaplastic thyroid carcinomas, as well as breast
cancer [8].
Papillary Carcinoma. PTC is a primary thyroid can-
cer of follicular epithelial cell origin with distinctive
nuclear features. PTC is the most common subtype of
thyroid cancer, comprising 80% of all thyroid carcino-
mas [9,10]. It is not possible to predict which tumors will
behave more aggressively; however, various staging sys-
tems provide parameters which can be used to determine
a patient’s prognosis. In PTC, aberrant methylation of
tumor suppressor genes such as TIMP3 (tissue inhibitor
of metalloproteinase-3) and DAPK (death-associated pro-
tein kinase) has been associated with tumor aggressive-
ness [11]. Gene expression analysis showed that cyclin
D1 (CCND1), is overexpressed in PTC, which is not
detectable in normal thyroid tissue [12]. Most mutations
found in papillary thyroid carcinoma involve the common
signaling pathway involving RET/PTC-RAS-BRAF. The
biological effects of this pathway include changes in the
cytoskeleton, cell proliferation, and differentiation [13].
Anaplastic (Undifferentiated) Thyroid Carcinoma. In
stark contrast to other thyroid carcinomas, undifferen-
tiated thyroid carcinoma is one of the most aggressive
malignancies known [14]. It accounts for < 5-14% of
thyroid malignancies. ATC is a tumor composed of undif-
ferentiated tumor cells with immunohistochemical or
ultrastructural evidence of epithelial derivation. In some
instances, it is present in association with a differentiated
carcinoma [2]. Most of these cases of undifferentiated car-
cinoma arise predominantly in association with PTC and
other poorly differentiated carcinomas [14]. ATC (about
90 %) occur in the background of differentiated thyroid
carcinoma (DTC), suggesting that DTC is a precursor
agent [2]. This accumulation of chromosomal abnormal-
ities along with ensuing gene dysregulation lead to loss
of cell cycle control, signal transduction activation, and it
is likely the underlying reason for its aggressive clinical
behavior.
Multiple pathways of genetic alterations could lead
to development of ATC, as not all ATC have identi-
cal genetic profiles. Most common genetic abnormalities
in ATC involve RET, p53, RAS, BRAF, and β-catenin
genes [2]. PIK3CA gene mutations have been described
in 23% of ATC [15]. This suggests a pathogenic role of
the PI3K/AKT pathway in the transformation of PTC
to ATC. The RAS-RAF-MEK-ERK-MAP kinase path-
way is a signal transduction pathway that regulates cell
proliferation and has also been associated with undif-
ferentiated thyroid carcinomas [16]. BRAF mutations
have been found in 29-70% of PTCs and are associ-
ated with oncocytic variants of papillary carcinoma [2,5].
RAS genes are GTPases related to signal transduction
for cell proliferation in the RAS-RAF-MEK-ERK-MAP
kinase pathway. RAS activating point mutations are found
in less than 10% of PTCs [2,17]. However, RAS has
been appeared more in the follicular variant of papillary
carcinomas [2].
Scope
Diagnosing the subtype of thyroid carcinoma with a high
level of accuracy and confidence is still a difficult task.
A better understanding of the genetic, molecular and
cellular mechanisms underlying the transition from dif-
ferentiated to undifferentiated thyroid tumor, as well as
their progression is necessary to develop more specific
and non-invasive treatments depending on the subtype
of carcinoma. This is the rationale behind the present
study. Here, by means of a Systems Biology approach, a
genome-wide analysis of 11 anaplastic (ATC), 12 follicular
(FTC) and 72 papillary thyroid carcinomas (PTC) sam-
ples, as well as 64 normal thyroid samples was carried
out to understand the genetic and biochemical differences
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and similarities among them. Through pathway analy-
sis, deregulation of genes involved in the inhibition of
matrix metalloproteinases pathway has been pointed out
as crucial for invasiveness, migration and metastasis.
The genetic analysis performed also suggests a pro-
gression from FTC to PTC and then to ATC, since a
significant change in the expression level of some genes
involved in determined pathways can be observed, mainly
related to arrest of cell cycle, apoptosis, cell to cell
signaling and mitosis. Furthermore, we established a
possible crosstalk in cell-death-and-survival events that
could be involved in the transition from PTC to ATC.
Finally, a series of 4 genes that could be useful to deter-
mine the cancer subtype was set up. PTX3, COLEC12 and
PDGFRA proved to differentiate anaplastic thyroid carci-
nomas from other subtype while GPR110 seems suitable
to become a biomarker for papillary thyroid carcino-
mas. This analysis can be applied to other carcinogenic
ailments as an alternative tool to discriminate among
different tumor subtypes.
Methods
A brief flowchart of the methods and samples used in this
study is presented in Figure 1.
Samples and pre-processing
Whole genome microarray gene expression data for 164
fine-needle extracted samples of thyroid tumors and nor-
mal thyroid tissue was obtain from publicly available
archive databases (Accession keys: GSE3467, GSE33630,
GSE3678, GSE5315). 64 belonged to healthy patients, 12
to FTC, 72 to PTC and 11 to ATC. 159 of those 164
samples proved viable to carry out the study in well-
characterized groups (after data quality control and pre-
processing). The actual sample was set up as follows:
• 64 normal thyroid (NT)
• 12 follicular thyroid carcinoma (FTC)
• 72 papillary thyroid carcinoma (PTC)
• 11 anaplastic thyroid carcinoma (ATC)
All samples were processed with the HG-U133_Plus_2-
Affymetrix HumanGenomeU133 Plus 2.0 Array. (Supple-
mentary Material 1). For microarray pre-processing and
differential analysis , we used the Gene Expression Analy-
sis Tool developed by Abraxas Biosystems ® implementing
a frozen Robust Multiarray Analysis (fRMA) -Background
correction and normalization procedure [18]. Annotation
was performed with the package hgu133plus2.db. Finally,
limma, an [R] library for modeling gene expression data
was used for differential expression analysis [19], con-
sidering as threshold the absolute value of the log-fold
change (LFC) > 1 and as significance measure the log-
odds statistic (B) B > 5 [20]. It is worth to mention that
no experiments were performed on human tissue in this
study; all the work presented here is analysis of previously
published gene expression data.
Gene expression analysis
In order to find Differentially Expressed Genes (DEGs) for
average expression levels of the three different subtypes
of carcinoma against normal controls, each subtype was
compared. Once the overexpressed and underexpressed
genes were established, a Gene Ontology (GO) Enrich-
ment Analysis was performed in order to find those path-
ways enriched in each carcinoma and observe the shared
gene sets for the three tumor subtypes. Significantly over-
expressed genes were coded as +, whereas underexpressed
molecules were coded as -. The gene ontology categories
of those shared genes were then analyzed to search for
common pathways or mechanisms that could present
crosstalk between subtypes.
Pathway analysis
Gene expression analysis (GEA) has become an extremely
used technique to study the coordinated behavior of
a large number of concomitant biological processes at
the molecular level, aiming to develop a systemic wide
phenomenological organismal characterization. How-
ever, GEA alone is often insufficient to gain biologi-
cal insight as one relies on a very large number of
differentially expressed genes commonly displaying dis-
parate behavior among samples. To further increase our
understanding and predictive capacities derived from
such high-throughput experiments, a number of methods
commonly termed Pathway Analysis have been devel-
oped in recent years [21-27]. This approach has been
espacially fit to study complex phenotypes such as those
associated with cancer [28]. Such complex cellular states
are usually the consequence of a number of system-wide
deregulation events rather than abnormalities at the sin-
gle molecule level. Thus gene-centered studies are rather
incomplete and often misguiding. Pathway analysis meth-
ods rely on strong probabilistic and computational meth-
ods to perform system-level analytics in carefully curated
information repositories. Such repositories may be struc-
tured Knowledge-based resources, as well as unstruc-
tured data- and literature- mining search and retrieval
applications.
Currently most of the existing pathway analysis meth-
ods are focused in the size of the sets of differentially
expressed genes belonging to a given biological path-
way. These methods are usually referred to as enrich-
ment methods (EM). Other alternative pathway analysis
techniques are based on the observation of the correla-
tion between lists of genes belonging to certain pathways
and their associated particular phenotypes (i.e. subsam-
ple sets), an approach known as functional class scoring
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Figure 1 Pipeline of the followedmethodology to perform this study. Red square represents the differences of the used samples. Blue square
points to the preprocessing of the data. Finally, the green square is depicted for the results of the analysis.
(FCS). Both EM and FCS have proved to be quite useful
yet still limited in their scope [21]. A number of advanced
alternatives have been suggested recently. In reference
[21], the authors combined a type of EM with pertur-
bation analysis assessed by non-parametrical bootstrap
procedures leading to the calculation of a global path-
way significance statistic. Further improvement on this
approach could be attained by resorting to probabilistic
graphical methods to infer sample-specific pathway activ-
ities. This reasoning together with an integrative view was
implemented by Vaske, et al. in a factor-graph based algo-
rithm called PARADIGM [22]. To advance more on a
mechanistic interpretation of pathway activation, a new
context-specific metric termed a Pathway Deregulation
Score (PDS) has been set forward [23]. PDS estimates
the extent to which the behavior of a certain pathway in
one sample deviates from that of a set of control sam-
ples. Once genome-wide PDS estimates are known, the
Pathifier algorithm mines them to search for sample-
specific pathway deregulation profiles and then statistical
enrichment analysis is performed [23]. The Pathifier algo-
rithmwas recently supplemented with Cox regression and
a regularized form of least-squares regression (the L1-
LASSO -or L1-norm least absolute shrinkage and selec-
tion operator method) to achievemore accurate prognosis
prediction.
Up to now, important computational and probabilis-
tic ways to improve quantitative analysis on the avail-
able biological information databases and sources have
been mentioned to underline their relevance. However,
another important avenue of improvement most certainly
relies on actual database build up. Biological information
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resources –both at the functional and molecular levels–
may be either unstructured (large scale experimental data
repositories, research papers and paper-collections as well
as in-process annotations) or structured at different lev-
els, from curated annotations and systematized reposito-
ries to quite specific and highly-curated knowledge-based
resources.
In some sense, both approaches seek to develop bet-
ter probabilistic and computational methods for path-
way data analysis to gain access to fine knowledge-based
sources of information. Hence, both are complementary.
A nice example of the combination of powerful quan-
titative methods applied to carefully curated knowledge
databases can be found in the recent paper by Verhaeg,
et al. [25]. In it, the authors rely on probabilistic network
Bayesian models for pathway activity inference applied to
a manually curated database for specific pathways (the
Wnt and ER pathways). Bayesianmodeling was performed
by using a clever modeling approach that considers three
elements in a signaling pathway: a set of transcription
complexes, a set fo target genes and a set of transcripts
(from microarray gene expression experiments) corre-
sponding to the target genes. The authors circumvent the
common assumption of using gene expression intensity
alone to model protein activity within a given pathway.
Though clearly relevant, computationally accurate
methods based in unstructured databases require a very
large number of experimental samples and eat up large
computational capabilities, since most of these accurate
methods rely in some form of higher statistical infer-
ence such as machine learning or Bayesian approaches.
However, due to limitations in sample availability (pre-
cluding the study datasets with counts in the hundreds-
to-thousands of samples), a two-way approach to pathway
analysis was followed based on mining both large scale
databases and highly curated knowledge bases –with all
interactions taken from actual experimental data – imple-
mented within the causal network philosophy [29,30].
Next, the Web-GESTALT enrichment tool was applied
to perform a pathway analysis to uncover enriched path-
ways according to the set of DEGs found for each carci-
noma subtype. Web-GESTALT is a quite comprehensive
large scale data-mining tool. It consists of 78,612 func-
tional categories across a dozen of large scale centrally and
public databases. It performs EM and calculates statistical
significance by means of FDR-corrected hypergeomet-
ric tests. We focused on large-scale commonalities and
differences among the enriched pathways, using a false
discovery rate (FDR) threshold = 0.01 and 2 genes as the
minimum, to allow the set of genes to belong to a group.
This procedure was applied as a broad, preliminary screen
to filter-out pathway information.
Causal networks (CNs) were then generated through the
Ingenuity Pathway Analysismethodology (IPA ®, QIAGEN
Redwood City www.qiagen.com/ingenuity). The approach
taken to generate such CNs relied heavily on a highly
curated knowledge-based source known as the Ingenu-
ity Knowledge Base (IKB). IKB contains about 40,000
nodes representing mammalian genes and their prod-
ucts (transcripts, proteins, miRNAs, second messengers,
etc.) as well as exogenous and endogenous chemical com-
pounds. To date IKB reports more than 1,480,000 inter-
actions between molecules. Such interactions are links
between the nodes. These links represent experimen-
tally observed cause-effect relationships relating to tran-
scription, expression, activation, molecular modification,
binding events and transport processes. Since these inter-
actions have been experimentally measured they can be
associated with a definite direction of the causal effect,
either activation or inhibition of the above mentioned
processes at a whole genome network-wide level. Conse-
quently, then information sources are highly-curated since
inference procedures are able to resort to two independent
aspects. On one hand, enrichment scores are determined
by hypergeometric tests or Fisher exact tests –depending
on the statistical dependency conditions on the variables
under consideration– that measure the overlap between
observed and predicted gene sets. On the other, Z-score
analysis asseses the match between observed and pre-
dicted up/down regulation patterns allowing for Bayesian
scoring of the results [27].
To elaborate, within the IPA/IKB approach a master
network is a directed multigraph G(V ,E) constituted by
nodes v ∈ V which are mammalian genes, proteins, miR-
NAS, second messengers or other molecules of interest
(C(V )  40, 000 with C the cardinality or size of the
set), whereas links e ∈ E are edges representing experi-
mentally measured causal relations (C(E) ≥ 1, 480, 000).
Since there can be more than one edge between two given
nodes –for instance transcriptional activation and phos-
phorilation of one molecule, say A, may be caused by a
single molecule B (albeit in a different state)– , the mas-
ter network G is a multigraph. Given that the interactions
may be either weighted or unweighted (depending on
experimental availability of reliable quantitative data), G
is in general a weighted, directed multigraph. For further
methodological details please look up for reference [27].
This causal master network proved to be invaluable as
a tool to find the common pathways in specific categories
of interest such as cell death and survival, as
well as cell to cell signaling processes for car-
cinoma subtype compared with the controls, since
these categories were considered relevant in carcinoma
progression. Finally, enriched pathways of each cancer
subtype was contrasted and analyzed to point out sig-
nificant differences among the three subtypes as well
so to establish possible mechanisms of progression and
malignancy.
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Results
Differentially expressed genes for each carcinoma subtype
Results for differentially expressed genes for all the con-
trasts under consideration may be found in Table 1,
Figure 2 and Additional file 1.
Overexpressed Genes. Comparisons between FTC, PTC
and ATC against the control show a subset of 37 common
upregulated genes (Figure 3A). Other interesting results
are that from 289 upregulated genes found in FTC sam-
ples, 162 were not shared by PTC or ATC. In the case of
ATC only 8% of the upregulated genes are shared by PTC
or FTC. Finally, in the case of PTC, approximately 40% of
the genes are shared by either ATC or FTC (Figure 3A).
Underexpressed Genes. In the case of the underex-
pressed genes, a subset of 95 genes are shared by the 3
tumor subtypes (Figure 3B). Additionally, in the case of
PTC underexpressed genes, only 72 of the 457 are not
shared while almost 400 are shared with FTC (52), ATC
(238) or both (95).
Gene ontology analysis suggests different enriched
processes for each carcinoma subtype
For the DEGs on each tumor subtype, GO enrichment
analysis was performed, showing significant differences
between groups (FTC, PTC and ATC). In Table 2 it is
shown how the most enriched categories for each subtype
are different:
• In the case of FTC, looking at the overexpressed
genes and their associated GO categories, we can see
that there are more categories related to cell
structure and scaffolding. For PTC, development and
extracellular processes are the most enriched
categories; whereas for ATC, the most enriched GO
categories correspond to cell division.
• The underexpressed genes for ATC are related to cell
junctions and axes determination. It can be argued
Table 1 Differentially expressed genes for FTC, PTC and
ATC
Type Total DEGs ↑ ↓ Top 5 ↑ Top 5 ↓
ZCCHC12 TENM1 DPT CHRDL1
FTC 579 289 290 CA12 CCL21
ARHGAP36 PRR15 DCN ADH1B
GABRB2 HMGA2 TPO DIO1
PTC 960 503 457 PRR15 ADH1B
CHI3L1 ZCCHC12 PKHD1L1 TFF3
POSTN MMP1 DIO1 TSHR
ATC 3220 1303 1917 VCAN TG
SPP1 TFPI2 SLC26A7 TPO
Differentially Expressed Genes (DEGs) for each subtype of carcinoma. It is also
shown the top-5 overexpressed and underexpressed genes.
that in ATC, the correct function of cell junctions
and axis determination are compromised. In the case
of FTC and PTC subtypes, extracellular functions,
development and cell structure are dampened. This
could be so, due to the fact that underexpressed
genes are highly shared in both subtypes.
Pathways Analysis for each carcinoma subtype
Different features for all the networks associated to
cell death and survival and cell to cell
signaling processes involving DEGs and mined from
each pathway were examined using IPA: preferential com-
partmentalization, highly connectedmolecules (hubs) and
differentially expressed molecules (Table 3).
IPA® generates by default the top 25 networks accord-
ing to the number of molecules resulted from the analysis.
These networks are divided by general functions. Net-
works in which the cell-death and survival as well as
cell-cell-signaling mechanisms are enriched were chosen.
This is due to the fact these mechanisms are highly related
to tumor progression and invasiveness.
Cell death and survival
Follicular Thyroid Carcinoma. The most important fea-
tures shared among the FTC networks in cell death and
survival processes are as follows: one of the networks
is mainly regulated by BCR, the others involve either
CTNNB1, the AKT-TP73 pathway or CD44-BAX-JUN.
Molecules aremainly located in the nucleus. TopDEGs for
each network were FOSB-, CCL2-, LPL+, JUN-, CD44+,
GDF15+, KLF4-, SLIT2-, SFRP2-, GATA5+ (Additional
file 2).
Papillary Thyroid Carcinoma. In the case of PTC, the
most important features shared among networks in cell
death and survival are as follows: One of the net-
works is mainly regulated by the female hormones (Cg,
FSH and LH), the others mainly involve caspases, AKT
pathway or CD44. Molecules are fundamentally located
in the plasma membrane and cytoplasm. Top DEGs for
each network were PPARGC1A-, SLC4A4-, HMGA2+,
PROM1-, IGSF1+, TIMP1+, SLC25A15, FHL1-, PAPSS2-
(Additional file 2).
Anaplastic Thyroid Carcinoma. There is only one sig-
nificant network for cell death and surival in ATC: As
it can be observed in Figure 4, it is mainly regulated
for metalloproteinases, caspases, tumor necrosis factor
receptor and tyrosine kinase activities. Figure 4 repre-
sents the molecules involved in a subpathway related
to cell death and survival signaling pathway (as
annotated in IPA/IKB), and are also present in the list of
differentially expressed genes in ATC samples for both,
underexpressed as well as overexpressed. All molecules
are depicted according to their cellular localization. The
links binding molecules represent experimentally-verified
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Figure 2 Volcano plots and heatmaps of the DEGs for each subtype of carcinoma. A) and B) represents the results for FTC, C) and D) for PTC
and finally, E) and F) shows the results of ATC. It is worth to mention that for the case of ATC, the Red and green dots are more that those pink, blue
and yellow. That is not the case for FTC or PTC. A volcano plot displays information about (the log-odds). Red dots are statistically significant
changes in gene expression for whole genome experiments over-expressed genes while green dots are statistically based in calculations for the size
of differential expression significant under-regulated genes (the log-fold change) and its statistical significance.
relationships in the IKB (See “Methods/Pathway Analysis”
subsection). The figure illustrates how MMP’s are over-
expressed mainly because their regulators are also over-
expressed and how caspases 3 and 7 are overexpressed
because their negative regulators are underexpressed.
Figure 4 also shows howMMP1, NUSAP1 and DEPDC1
are the most overexpressed genes. Concerning NUSAP1
and DEPDC1, the only DEG that regulates them is
FOXO1, a very ubiquitous transcription factor. In the case
of matrix metalloproteinase 1, there are several regula-
tors, most of them (with the exception of FOXO1 and
Jnk) also overexpressed. The fact that MMP1 and MMP3
are highly overexpressed suggest that the mechanisms for
migration and invasiveness may be active. On the other
hand, NUSAP1 is a nucleolar-spindle-associated protein
that plays a role in spindle microtubule organization. High
levels of this protein have been observed in cervical cancer
[31]. DEPDC1might play an essential role in the growth of
bladder cancer cells [32]. DEPDC1A knockdown delayed
the growth of human myeloma cell lines (HMCLs), with
a block in G2 phase of the cell cycle, p53 phosphoryla-
tion and stabilization, and p21 (Cip1) accumulation [33].
Hence DEPDC1A overexpression in ATC may be related
with the growth of cancer cells. Other interesting features
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Figure 3 Venn diagrams for the number of DEGs. Both for overexpressed (A) and underexpressed (B) genes. For both cases, the Red circle
contains FTC genes, yellow circles are for PTC and the green ones present ATC genes. The columns of the right show the shared genes for the three
cancer subtypes.
are that KIF18, a member of the kinesin superfamily
of microtubule-associated molecular motors is overex-
pressed whereas SPINT2 is a putative tumor suppressor
that appears to be underexpressed.
IPA/IKB algorithm for CN was applied as follows:
First, the list of molecules in the cell death and
survival subpathway were analyzed seeking statistical
enrichment in our DEG set. After statistical significance
was achieved, the algorithm retrieves a list of experimen-
tally verified interactions from the master network and
depicted them in a pathway color-coded according to the
average fold-changes in the GEA for the contrast under
consideration.
Cell-to-cell signaling
Follicular Thyroid Carcinoma. In these networks none
of the hubs are differentially expressed in the path-
ways. Plasma membrane is the most important compart-
ment. Top DEGs are: ZMAT3+, GJB6-, EPHB1-,EPHA3-,
COL13A1+, CDH16- and XPR1 (Additional file 2).
Papillary Thyroid Carcinoma. Again, there are no dif-
ferentially expressed hubs in PTC. Plasma membrane is
once more the most important compartment. The top
DEGs are CITED2-,GHR-, CDH3+, FN1+, SHANK2-,
SERPINA1+, CLMN- (Additional file 2).
Anaplastic Thyroid Carcinoma. In contrast, all hubs
are DEGs and perhaps more outstanding, all of them
are overexpressed: PLAU+, IL1B+, CCL20+, IL1RN+,
MYD88+, IL8+, CD14+, TLR2+. All molecules signalize
in plasma membrane or extracellular matrix. Finally, the
top DEGs are PLAU+, PLAUR+, SPP1+, LRP1B-,PPAP2B-
, SLC4A4-, TSHR-, PDE8B-, FCGR2A+, TNFA1B6+, TG-,
CXCL5+, CD86+, CLEC7A+, IL8+, CCL21-, TLR2+. For
ATC most of the signaling molecules are receptors. It
seems that endocrine-and-paracrine-related signaling is
more prevalent than in FTC or PTC. Interestingly enough,
even when, in general, ATC possess a higher number
of underexpressed genes (1917 vs. 1303 overexpressed),
most molecules in ATC-related signaling pathways are
overexpressed, pointing out to exacerbated extracellular
signaling in ATC (Figure 5).
Pathway commons analysis fromWEB-gestalt
An important result is the set of shared pathways among
the different subtypes of carcinomas (Figure 6). While
FTC and PTC only share the P53 effectors pathway, PTC
and ATC share α9β1 integrin signaling event; β1 integrin
cell surface interactions, integrin family surface interac-
tions, proteoglycan syndecan-mediated signaling events
and finally VEGF & VEGFR signaling network. Enrich-
ment analysis of this gene list shows three main pathways:
ATR signaling pathway (adj_p-value= 0.0413), integrins
in angiogenesis (adj_p-value= 0.0413) and ATM path-
way (adj_p-value= 0.0452). For a detailed account on the
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Table 2 Gene ontology analysis of the differentially expressed genes for FTC, PTC and ATC
Subtype (Exp) GO-ID p-value corr p-value x n X Description
FTC ⇑
9987 4.8469E-9 1.2888E-5 185 9365 264 cellular process
44459 2.6863E-8 2.9147E-5 61 1998 264 plasma membrane part
786 3.2885E-8 2.9147E-5 10 64 264 nucleosome
32502 2.4620E-7 1.6366E-4 82 3235 264 developmental process
6334 3.6737E-7 1.9537E-4 10 82 264 nucleosome assembly
31497 5.7722E-7 2.5580E-4 10 86 264 chromatin assembly
7155 8.6760E-7 2.6280E-4 29 711 264 cell adhesion
22610 8.9259E-7 2.6280E-4 29 712 264 biological adhesion
65004 9.8169E-7 2.6280E-4 10 91 264 protein-DNA complex
assembly
30054 9.9358E-7 2.6280E-4 24 521 264 cell junction
PTC ⇑
5576 8.4568E-20 3.4089E-16 124 2025 471 extracellular region
32502 2.2428E-18 4.5203E-15 164 3231 471 developmental process
44421 7.1367E-18 9.5893E-15 77 985 471 extracellular region part
48731 1.0396E-17 1.0476E-14 134 2420 471 system development
48856 1.4340E-17 1.1561E-14 142 2653 471 anatomical structure
development
7275 1.2464E-15 8.3739E-13 148 2969 471 multicellular organismal
development
9611 3.1138E-15 1.7931E-12 51 541 471 response to wounding
31012 6.5039E-14 3.2771E-11 38 340 471 extracellular matrix
48513 1.1744E-13 5.2599E-11 101 1790 471 organ development
48518 1.4424E-13 5.8143E-11 116 2207 471 positive regulation of
biological process
ATC ⇑
22403 2.6565E-31 1.6569E-27 105 436 1205 cell cycle phase
7049 5.2100E-30 1.6247E-26 147 794 1205 cell cycle
279 1.0473E-29 2.1774E-26 91 352 1205 M phase
22402 1.9707E-29 3.0727E-26 121 583 1205 cell cycle process
278 2.8071E-28 3.4578E-25 93 381 1205 mitotic cell cycle
280 3.8808E-28 3.4578E-25 71 233 1205 nuclear division
7067 3.8808E-28 3.4578E-25 71 233 1205 mitosis
87 4.7977E-28 3.7404E-25 72 240 1205 M phase of mitotic cell cycle
6950 5.0373E-27 3.2463E-24 240 1773 1205 response to stress
48285 5.2048E-27 3.2463E-24 71 242 1205 organelle fission
FTC ⇓
44421 3.9892E-20 1.2027E-16 59 984 270 extracellular region part
5576 1.5267E-18 2.3015E-15 84 2024 270 extracellular region
5615 3.5497E-16 3.5674E-13 46 746 270 extracellular space
9653 3.2978E-15 2.4857E-12 58 1216 270 anatomical structure morphogenesis
48856 2.0741E-14 1.2507E-11 90 2654 270 anatomical structure development
32502 3.6213E-13 1.8197E-10 99 3232 270 developmental process
48731 1.5184E-12 6.5398E-10 81 2420 270 system development
7275 2.0597E-12 7.7626E-10 92 2969 270 multicellular organismal development
31012 1.4050E-11 4.7067E-9 26 340 270 extracellular matrix
48513 4.7085E-11 1.4196E-8 64 1790 270 organ development
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Table 2 Gene ontology analysis of the differentially expressed genes for FTC, PTC and ATC (Continued)
PTC ⇓
44421 7.8517E-13 2.8376E-9 61 985 404 extracellular region part
5615 8.2894E-10 1.0196E-6 46 747 404 extracellular space
48856 8.4640E-10 1.0196E-6 107 2655 404 anatomical structure development
48731 2.1381E-9 1.9317E-6 99 2421 404 system development
5576 2.7064E-9 1.9562E-6 87 2026 404 extracellular region
9653 4.1464E-9 2.4975E-6 61 1217 404 anatomical structure morphogenesis
48513 2.6665E-8 1.3767E-5 77 1791 404 organ development
7275 5.2835E-8 2.3868E-5 110 2970 404 multicellular organismal development
32502 5.9933E-8 2.4067E-5 117 3233 404 developmental process
31012 7.5072E-8 2.7131E-5 26 340 404 extracellular matrix
ATC ⇓
5737 1.2083E-12 7.0080E-9 837 7628 1632 cytoplasm
5622 1.4044E-9 4.0728E-6 1147 11273 1632 intracellular
43296 4.8770E-9 9.4289E-6 27 85 1632 apical junction complex
44444 8.0946E-9 1.1737E-5 574 5140 1632 cytoplasmic part
16327 1.1319E-8 1.3130E-5 27 88 1632 apicolateral plasma membrane
70160 2.1881E-8 1.7096E-5 24 74 1632 occluding junction
5923 2.1881E-8 1.7096E-5 24 74 1632 tight junction
44424 2.3581E-8 1.7096E-5 1107 10919 1632 intracellular part
55114 5.1010E-7 3.2873E-4 98 647 1632 oxidation reduction
5911 6.8676E-7 3.9832E-4 40 192 1632 cell-cell junction
It is shown a set of the top ten categories for each case, overexpressed (⇑) and underexpressed (⇓).
It is shown the GO-ID, the p-value, adj. p-value, number of genes present in the set and the total of number of genes involved in that GO categorie. Finally, the name
of the GO is also shown.
Table 3 IPA analysis of signaling pathways involved in cell-death and cell-to-cell signaling events
Category Subtype Compartment Hubs DEGs
Cell Death
ATC M, C, N MMP1+, MMP3+, JNK-, FOXO1-, CASP3+, CASP7+ MMP1+, NUSAP1+, DEPDC1+, SPINT2-
FTC
M BCR*, NFKB*, ADRB2- FOSB-, CCL2-, LPL+
C IL12*, IFA*, CD3*, CD44+, BAX+, HSP70*, JUN- JUN-, CD44+
N CTNNB1*, KCNIP4-, PGR* GDF15+, KLF4-, SLIT2-
N AKT*, E2F1*, TP73*, E2F* SFRP2-, GATA5+
PTC
M, C CG*, FSH*,LH* PPARGC1A-, SLC4A4-, HMGA2+
M, C PI3K family*, AKT*,BCR*, IGs* PROM1-, IGSF1+
C TGM2+, Caspases* TIMP1+, SLC25A15, FHL1-
N CD44+, AKT1*, GLI1*, POU5F1* PAPSS2-
Cell-Cell Signaling
ATC
M CG*, Secretase gamma*, PLAU+ PLAU+, PLAUR+, SPP1+, LRP1B-,PPAP2B-, SLC4A4-
E IL1B+, CCL20+, IL1RN+ TSHR-, PDE8B-, FCGR2A+, TNFA1B6+, TG-
M IFNA*, IFNB*, IL12*, MYD88+ CXCL5+, CD86+, CLEC7A+
M IL8+, CD14+, TLR2+ IL8+, CCL21-, TLR2+
FTC
E, M, C IL8*, IL13*, COL18A1*, HB*, CBL* ZMAT3+, GJB6-, EPHB1-,EPHA3-
M Estrogen receptor*, ITGB1*, CD46*, SPDEF*,FOXA1* COL13A1+, CDH16-
M { } XPR1+
PTC
M, C NFKB*, GH* CITED2-,GHR-, CDH3+
M, C MAPK1*, F2*, HSF1* FN1+, SHANK2-
E IFNG*, IL1A*, p73* SERPINA1+, CLMN-
It is shown the compartment in which the found molecules are more abundant (M for plasmamembrane; C for cytoplasm; N for nucleus and E for Extracellular Matrix),
The most connected molecules (hubs) and the most differentially expressed genes. The sign (+,- and *) represent overexpression, underexpression and no-change
with respect to control.
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Figure 4 Pathway for a network related to cell-death and survival process in the anaplastic thyroid carcinoma. This graph shows the
interaction network of the differentialy expressed genes of ATC which have a role in death and survival events. Red molecules are overexpressed
and green molecules shows underexpression. Color intensity represents the difference between the ATC samples compared with the normal ones.
Notice the high degree of conection of MMP1 and Jnk molecules. It is also worth to mention that most molecules in the plasma membrane are
overexpressed meanwhile those in nucleus and cytoplasm have low expression values.
enriched categories exclusive to each tumor subtype see
the Discussion Section.
Enriched pathway commons from IPA
IPA was used to investigate the pathways shared by the
DEGs from FTC, PTC and ATC. It is important to men-
tion that the most enriched pathway in ATC was the one
related to Inhibition of Matrix Metalloproteinases (IMM).
PTC, however, is poorly enriched and FTC is completely
absent (Figure 7) This might be indicative of invasiveness
enhancement, migration, colonization and metastasis in
ATC with respect to PTC or FTC.
Validation
It is known that the cornerstone of science (and in partic-
ular of computational biology) is validation of the results
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Figure 5 Pathway for a network related to cell to cell signaling process in the anaplastic thyroid carcinoma. Please notice the
overexpression of PLAU, PLAUR and SPP1.
and alternative hypothesis testing. This is specially true
in the case of high throughput gene expression analyses
like those performed in this work. In order to comply with
such an important requirement we implemented the same
analysis pipeline we follow in our original experimental
design in two independent thyroid cancer gene expression
datasets.
In this section we will present results of the validation
procedures related to our main findings in this work. The
complete results for gene expression analysis for the val-
idation sets (and also for the original dataset) as well as
other related calculations are included as supplementary
material.
In order to validate the results obtained by the differen-
tial expressions analysis in our dataset, we perform differ-
ential analysis on two independent datasets. In the case of
the top differentially expressed genes, we found that for
those genes the expression levels resulted in agreement
with our original analysis in 27 out of 30 comparisons.
Results are shown in Table 4.
Regarding the presence of genes whose differential
expression profiles may provide us with a means of
molecular differentiation between subtypes (i.e. can-
didate biomarker molecules), we found four of them
PTX3, COLEC12, and PDGFRA (whose overexpression
is likely indicative of an ATC phenotype) and GPR110
(whose overexpression may indicate PTC). We vali-
dated those gene expression profiles by a comparison
of their actual probability distribution across samples
in the validation sets. Boxplot-outlier analysis as well
as Receiver-Operator Characteristic and Area-under-the-
curve calculations (ROC-curves and AUC respectively)
for the validation datasets were performed in an iden-
tical manner to the analysis in Figures 8 and 9. Results
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Figure 6 Venn diagrams for shared pathways from theWebGestalt for common pathways analysis. It is remarkable that the non-shared
pathways for FTC (the less malignant) are related to DNA repairing and Regulation of cell cycle; for PTC the paracrine events and for ATC the mitosis
pathways. The shared pathways also reflects the inter-type events. Again, FTC-PTC share Direct p53 effectors, meanwhile PTC-ATC share ce–to-cell
signaling pathways as well as grow factor-related events.
were consistent (Table 5), detailed plots are included as
Additional files 3 and 4.
Regarding the phenomenon of dysregulation of the Inhi-
bition of Matrix Metalloproteinases Pathway in ATC we
perform IPA/IKB causal network calculations (see the
Pathway Analysis subsection in Methods) for the two
independent validation datasets to check whether this was
the case. The results for the three tumor subtypes are pre-
sented in Table 6. As one can see there, IPA/IKB pathway
analysis for FTC and PTC show no statistically signifi-
cant dysregulation of this pathway (as expected). In the
case of ATC, this pathway resulted dysregulated, reach-
ing significance level in two out of three experimental
datasets.
Datasets chosen for validation are publicly available and
reported in Additional file 4. It is worth mentioning that
although it would be highly desirable to have higher sam-
ple counts for the inference and validation of results, at
the time there is no public availability of larger exper-
imental datasets. Future lines of inquiry would be by
necessity associated with the development larger whole
genome gene expression experimental datasets for thyroid
neoplasms.
Discussion
During this research, a model of thyroid carcinoma pro-
gression based on genome-wide expression datasets has
been built by using three different approaches and two
validation sets. According to the differentially expressed
genes obtained in our samples, we suggest differences
between the three cancer subtypes at the molecu-
lar level have an important impact on signaling. This
impact induces observed phenotypic differences. Using
WEBGestalt (see “Methods”) for dissecting pathways, the
main biological features associated with the DEGs were
dissected for each subtype. By using IPA, pathways and
their relations were able to be observed, mainly those
in which the DEGs participate deepening knowledge
on the mechanistic functions of the molecules involved
in each subtype. Furthermore, integrating three analy-
sis tools proved to be useful for an insight into the
relevancy of some molecules on the progression of thy-
roid carcinoma; mainly, molecules involved in cell to
cell signaling events as well as cell death and
survival cell-death processes, namely, the metallopro-
teinases, the caspases and their regulators. Moreover, the
concomitant effects that several pathways have on certain
key molecules related to cell-death and migration events
were determined.
Invasiveness andmigration events in ATC could be
exacerbated by synergistic pathways
In addition, insight was achieved regarding processes
related to growth of tumor mass and tissue invasion
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Figure 7 Inhibition of matrix metalloproteinases pathway for each case: A) FTC, B) PTC and C) ATC. It is shown the contrast in the
differentially expressed genes for each case. FTC does not have DEGs, PTC has only a few but ATC has very high differentially expressed genes,
specially, ADAM , TIMP and MMPs, suggesting a very important role of this pathway in the progression of ATC.
and the degradative action of extracellular MMP or
membrane-type MMP (MT-MMP) subfamily. Proteins
encoded by MMP and MT-MMP genes can alter cell-
cell and cell-ECM junctions; both mediate the release and
activation of autocrine or paracrine signaling molecules
such as angiogenic activators as well as activate or
deactivate cell surface receptors, promoting invasive-
ness and metastasis [34]. On the other hand, matrix
metalloproteinase-1 may be responsible for the aggres-
siveness or bone metastasis of poorly differentiated thy-
roid carcinoma [35].
Proteolytic activities of MMP and MT-MMP are tightly
regulated by the family of tissue inhibitors of metallo-
proteinases (TIMP) in a reversible fashion [36,37]. Unlike
TIMP1, TIMP2, and TIMP4, which are secreted in solu-
ble form, TIMP3 is present only in association with ECM.
TIMP3 has been shown to promote apoptosis whereas
TIMP1 is active in blocking apoptosis. Overexpression of
TIMP2 protects cancer cells from apoptosis [38,39].
Some MMP have anti-angiogenic action, such as
metalloproteinase disintegrin activity thrombospon-
din motif (ADAMTS). This subgroup of MMP has
thrombospondin-like domains, and it has been observed
that some of its members are able to block the activa-
tion of VEGF-induced angiogenesis [40]. Members of
the ADAM family are cell surface proteins with a unique
structure possessing both potential adhesion and protease
domains. ADAMTS encodes a protein that cleaves many
other proteins including TNF-α and E-cadherin.
In addition, other proteins that act as inhibitors of
MMPs have been described, noting that some contain
domains homologous to domains of the TIMPs. For exam-
ple, the reversal inducing protein cysteine-rich motif
Kazal (RECK) is an inhibitor that has a regulatory role
in the integrity of the extracellular matrix in angiogenesis
[41] that is overexpressed in ATC.
On the other hand, taking into account the molecules
involved in cell to cell signaling events, the
most DEG was osteopontin (SPP1), which has been found
disregulated in several subtypes of cancer [42] which in
turn is linked to PLAU and PLAUR, also highly overex-
pressed. Nearly all normal samples were underexpressed
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Table 4 Validation of top differentially expressed genes in
PTC, FTC and ATCwith two independent datasets





































For this analyisis the 5 top overexpressed and underexpressed genes of our
datasets was tested against two independent genome-wide gene expression
databases (available in Additional file 4). The first column shows
over/under-expression of each gene within our set; second column shows the
gene names. Gene validation status (cols. 3 and 4) shows that 27 out of 30
relationships were consistent with our original analysis.
for SPP1. Some thyroid adenomas have been found weakly
SPP1 positive, whereas many carcinomas were strongly
positive [43].
As it has been noted on previous work [44]: CST6,
CXCL14, DHRS3, and SPP1 are regulated by BRAF sig-
naling and may play a role in papillary thyroid car-
cinoma pathogenesis. We suggest that SPP1 might be
used as a candidate diagnostic and prognostic marker
for these tumors. Furthermore, given the role of the
SPP1-CD44v6 axis in PTC cells, it has been suggested
that CD44 and/or SPP1 may be molecular targets for
therapeutic intervention in aggressive PTCs [45]. PLAU,
a serine protease involved in degradation of the extra-
cellular matrix and possibly tumor cell migration and
proliferation [46,47] was also overexpressed in our ATC
data.
Despite the fact that some previous results point out
to SPP1-related cell signaling in PTC, we found SPP1 as
one of the most DEGs in ATC. Taking into account that
the most differentially expressed gene involved in cell
death and survival was MMP1 –a protein also
related to migration and adhesion– (Figure 4) and the
most DEG in cell to cell signaling was SPP1
(Figure 5), we were also able to establish that invasiveness,
migration and proliferation via PLAU and MMP could
occur autonomously and they may exert an increased
synergistic proliferative phenotype; thus, increasing
aggressiveness.
From our results, LRP is underexpressed in ATC. Low
expression of LRP at the cell surface was associated to
elevated extracellular MMP2 and urokinase plasminogen
activator (uPA) activities as well as to high invasive-
ness properties [2]. Thyroid carcinoma aggressiveness was
widely increased by exogenous uPA. Anti-uPA antibody
treatments abolished both basal and receptor-associated
protein-induced thyroid cell invasion [48]. Overall, our
results are consistent with the fact that, in the most
aggressive carcinoma (ATC), LRP gene is underexpressed,
which could favor thyroid carcinoma cell invasion.
Inferred progression FTC-PTC-ATC
The common-pathway-analysis obtained by the
WEBGestalt tool showed some shared networks in the
three subtypes of carcinoma. This sharing between the
different subtypes results revealing, because it is possible
to try to establish a timeline of progression related with
the main activities of those pathways, since the most
enriched pathways for each cancer subtype lies on dif-
ferent categories which in turn are related to different
processes in the cell. These processes are associated to
distinct moments in the cell’s lifespan.
Starting with FTC, the less aggressive carcinoma, the
principal functionalities are related to DNA damage
repair and cell cycle regulation; i.e. the repairing machin-
ery is available and works to face damage of cancer cells.
This cancer subtype shares Direct p53 effectors pathway
with PTC subtype. For PTC the most enriched pathways
found was mainly related to cell to cell signaling
events and adhesion to extracellular matrix;
those pathways seem to be involved in events of paracrine
signaling, suggesting an incipient invasion of cancer cells,
but without other hallmarks of cancer, like evasion of
apoptosis or immortalization. Finally, PTC shares with
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Figure 8 Possible biomarkers to differentiate among thyroid carcinomas. A) Venn diagrams which contain the overexpressed genes of ATC
together with those which are underexpressed in FTC and PTC. B) follows the same logic but the overexpressed genes belong to PTC meanwhile
the underexpressed are for ATC-FTC. C) Boxplot of the expression levels of those genes for each case with respect to control.
ATC some cell to cell signaling events as well
as mitosis processes (VEGF and VEGFR signaling net-
work [49]). The rest of enriched categories in ATC are
focused on cell cycle progression, indicating metastasis
and invasiveness, thus suggesting FTC → PTC → ATC
progression.
Further support for this assertion lies in the fact that in
most cases ATC arise in association with a differentiated
carcinoma –mainly PTC– as well as some poorly dif-
ferentiated lesions [2,5,14]. Hurtle cell tumors and other
follicular carcinomas are also known to be able to undergo
anaplastic transformation [2,14].
In PTC, aberrant methylation of tumor suppressor
genes such as TIMP3 and DAPK, has been associated with
tumor aggressiveness [11]. TIMP1 and TIMP3 has been
reported to be underexpressed in PTC and FTC, respec-
tively [11]. During our analysis, DAPK1 and DAPK2 are
underexpressed in FTC and ATC, respectively, but not in
PTC. However, contrary to data obtained by Hu et al. [11],
TIMP1 is overexpressed in our PTC samples (as is also in
ATC).
Gene expression analysis has previously demonstrated
that cyclin D1 (CCND1) is overexpressed in PTC [12]. In
our data CCND1 is overexpressed in PTC and FTC as it
was previously discussed. CCND2 is underexpressed in
ATC and there are no overexpressed CCNDs in anaplastic
thyroid carcinoma, suggesting an abscence of progression
of the cell-cycle via cyclins in ATC.
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Figure 9 ROC curves for the possible biomarkers to differentiate among thyroid carcinomas. For each molecule it is showed the ROC curve
as well as the Area Under the Curve (AUC) value. The color code is the same than in Figure 8. A) curve for PTX3; B) COLEC12; C) PDGFRA. Those 3
genes were overexpressed in ATC meanwhile underexpressed in PTC. D) shows GPR110 ROC curve, which resulted overexpressed in PTC and
underexpressed for ATC. Results are in full agreement with those in Figure 8.
Table 5 Validation profile for the candidate biomarker




























Validation of the Gene expression profile for PTX3, COLEC12, PDGFRA and
GPR110 in two independent datasets. First column shows gene names, second
column refers to the original profile as in Figure 8, third and fourth columns refer
to the validation status respect to the original profile.
Table 6 Validation of the status of the inhibition of matrix
metalloproteinases pathway in PTC and ATCwith other
sample subset
Subtype Dataset 1 Dataset 2 Dataset 3
(original) (validation 1) (validation 2)
FTC Not significant Not significant Not significant
PTC Not significant Not significant Not significant
ATC Active Not significant Active
For this IPA/IKB analyisis, the Inhibition of Matrix Metalloproteinases (IMMPP)
pathway was tested against two independent genome-wide gene expression
databases. The IMMPP resulted with no statistical significance (at the
p− value= 0.01 level) for both FTC and PTC in all three cases (original dataset
and two independent validation datasets) as expected. However, despite the
statistical significance of the whole pathway, somemolecules related to IMMPP
in PTC resulted differentially expressed (depicted in Figure 7B). In the case of
ATC, the IMMPP resulted dysregulated. However only two out of three
experimental datasets (the original and one of the validation sets) reached
statistical significance (p− value 10−8 and 10−5, respectively).
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Figure 10 Relevant crosstalk of altered signaling pathways involved in cell death for PTC and ATC.Molecules enriched in PTC are depicted
in turquoise meanwhile those enriched in ATC are depicted in yellow. Notice that both pathways start in both intra and extracellular space and also
both culminate with the inhibition of caspases.
Possible crosstalk in cell-death-and-survival events could
be involved in the transition from PTC to ATC
Enriched pathways of cell death and survival
events contain molecules relevant for each subtype of
carcinoma. However, different tumor subtypes can share
some elements, indicating that shared molecules partici-
pate in both subtypes, possibly in a different fashion. In
our case, caspases 3 and 7 were overexpressed as well
as both PTC and ATC, being also regulated by distinct
molecules and showing a different expression levels. For
the case of ATC, caspases 3,7 were shown being regulated
by Jnk, GATA6, SH3RF1 and PIAS1: all of them underex-
pressed. On the other hand, PTC presents caspases 3,7 at
normal expression levels and being regulated by TIMP1.
TIMP1 and its regulators are overexpressed, making thus
a difference in the mechanisms of action of caspases.
However, TIMP1 is also overexpressed in ATC, suggest-
ing that the disregulation of the caspases activity could be
determined by changes of its modulators. Furthermore,
this crosstalk between PTC and ATC pathways may diffi-
cult the action of therapeutics against caspases, since they
can be multiple-modulated (Figure 10).
Our results are supported by several other experi-
ments as well as recent literature. For example, LGALS3
(galectin-3) is overexpressed in ATC and PTC, as it
is mentioned by Wiseman et al. [49], as well as p16
(CDKN2A) and HMGA2. Changes in gene expression
profiles for LGALS3 provide insights into stages of tumor
progression. For example, a study of 100 benign and 105
malignant thyroid tumors using a panel of 57 molecular
markers found an association of tumor pathology with the
expression of a subset of markers including cytokeratin 19
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(CK19), LGALS3, HBME-1, VEGF, AR, p16, and AURKA
[49].
As it was pointed above, expression of HMGA2 corre-
lates with malignant penotype of thyroid tumors and can
be used as a tool to differentiate malignant from benign
lesions [50,51]. HMGA2 was found overexpressed in the
three cases, reinforcing its role to differentiate.
Pathway dissection for cell-to-cell signaling
Since a significant difference among the differentially
expressed molecules involved in the IMM pathway was
found for each subtype of carcinoma, we decided to dis-
sect thoroughly the cell-to-cell singling pathways. Our
analysis showed the following:
• FTC:Metalloproteinases and TIMP3 are
underexpressed, indicating an absence of migration
or invasiveness. On the other hand, the Bax-pathway
is also inhibited, which may be indicative of an
absence of apoptotic processes.
• PTC:MMP1 is overexpressed, but its inhibitor
TIMP1 is also overexpressed, suggesting a
competition for the progression of invasiveness.
Caspases are overexpressed too, thus leading to
conflicting signals of cell death and progression.
• ATC: One of the most differentially expressed
molecules in the whole analysis was the
metalloproteinase MMP3 suggesting migration and
invasion processes. Furthermore, caspases 3 and 7 are
also overexpressed, possibly due to the
downregulation of Jnk via ANXA2 inhibition.
DEGs downregulate some pathways meanwhile increase
others
After finding sets of shared underexpressed genes, we
found only 11 genes involved in 10 pathways. The genes
in question are CHRDL1, EGR2, FGFR2, FOSB, IPCEF1,
JUN, KCNIP4, NCAM1, SCN3B, TBC1D4 and TGFRB3.
The associated pathways are the following:
1. EGF-receptor ERB1 signaling pathways
2. IL-3-mediated signaling events
3. Glypican pathway
4. LKB1 signaling events
5. Endothelins pathway
6. Class I PI3K signaling events mediated by Akt
7. Arf6 trafficking events
8. Arf6 downstream pathway
9. PDGFRB signaling pathways
10. Class I PI3K signaling events
Those pathways seem to be dampenened in some man-
ner in all three cancer subtypes.
Like, the set of 35 overexpressed shared genes present
only 1 common pathway: Integrin family cell surface inter-
actions, with 5 genes: GDF5, EDIL3, ITGA1, TNFRSF10B
and EPS8. To our knowledge, none of these genes have
been found associated to thyroid carcinomas. We noticed
as well that PDGFRA could serve as a biomarker for ATC,
since it is underexpressed in FTC and PTC. It is the same
case for COLEC12 and PTX3.
Possible candidate biomarkers to differentiate among
thyroid carcinomas
ATC is quite different at the gene expression level than
the other two tumors. ATC is the cancer subtype with
more underexpressed genes than overexpressed ones.
Comparison of genes overexpressed in ATC while under-
expressed in FTC and PTC are PTX3, COLEC12 and
PDGFRA (Figure 8A). DNA microarray analysis has
shown platelet-dervived growth factor receptor (PDGFR)
overexpression in ATC relative to well-differentiated thy-
roid cancer [52]. Interestingly enough PDGFRA promotes
lymphatic metastases in papillary thyroid cancer [53].
Also, inhibitors of PDGFR can supress anaplastic thy-
roid carcinomas [54]. Both Akt and the PDGF/PDGFR
system play crucial roles in cell proliferation, differentia-
tion, migration, invasion and tumorigenesis, and develop-
ment and metastasis of ATC. These findings imply that
autocrine activation of PDGF-α receptor plays a crucial
role in the carcinogenesis of thyroid cells [55]. GPR110
in turn is overexpressed in PTC while underexpressed in
ATC and FTC (Figure 8B). GPR110 has been hypothesized
to be oncogenic and has been observed overexpressed in
lung and prostate cancer [56]. PTX3 is an inflammatory
factor involved in fertility [57] and also, its overexpression
has been associated to lung cancer [58] (Figures 8C and 9).
Validation for this results are showed in the supplemen-
tary material.
Summary of main findings
By means of a genome-wide analysis, differentially
expressed genes were found for three different subtypes
of thyroid carcinoma: Follicular (FTC), Papillar (PTC) and
Anaplastic (ATC). By analyzing their differences we have
pointed out a possible progression from FTC to PTC and
after that to ATC. We also have shown that those three
subtypes share both overexpressed and underexpressed
sets of genes determining that most enriched pathways
for each subtype of carcinoma are different and these
differences, could be related to the aggressiveness and
invasiveness. Finally, an interesting result obtained by the
pathway analysis is that metalloproteinases disregulation
could be involved in the progression from PTC to ATC
in an irreversible fashion; the underexpression of TIMP3
gene in ATC could be responsible for the matrix metal-
loproteinases inhibition pathway being unregulated, thus
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facilitating invasiveness and the concomitant metastasis.
Moreover, overexpression of PLAU, PLAUR and SPP1
could exert an increased cell-to-cell interactions making
thus an enhanced metastatic effect.
Regarding the set of differential genes that we suggest
may constitute candidate biomarkers (PTX3, COLEC12
and PDGFRA for ATC and GPR110 for PTC), one thing
could be said: since these molecules have been scarcely
studied they may well constitute interesting targets for
directed research in relation to thyroid carcinoma.
In an attempt for summarize our findings we can state
the following:
1. There is evidence to suggestting progression of
thyroid carcinoma could happen from FTC to PTC
and finally to the undifferentiated ATC.
2. FTC and PTC share some characteristics –genes and
pathways– which are related to DNA damage repair
or cell cycle arrest. At the same time, PTC and ATC
share pathways and genes related to
cell to cell signaling.
3. PTX3, COLEC12 and PDGFRA could be used as
biomarkers to differentiate ATC from FTC or PTC
since these 3 genes are overexpressed in ATC
meanwhile underexpressed in the other two subtypes.
Conclusions
Regulation of biochemical pathways in cancer is an excit-
ing and ever changing field. A number of challenges
need to be overcome though. In the case of undiffer-
entiated thyroid carcinoma there is a still a need for
comprehensive genome-wide studies in larger sample
databases. The required amount of information typical of
current Systems Biology studies demands that more and
more.
Pathway crosstalk is one of the biggest difficulties to
perform correct therapies. This work is an attempt to dis-
sect important pathways with the aim to find crosstalk
points in order to develop more specific drugs. Even
when hundreds of genes resulted differentially expressed
in tumor samples, this study focused on those genes in
which the most enriched pathways are involved, to dis-
tant ourselves from a gene-centric approach in favor of a
pathway-centeredmechanistic analysis. More work on the
functionality of DEGs and their related pathways in such
complex phenotypes is needed.
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